Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2822 Outcome of Systemic Therapy in Secondary High-Grade Pancreatic Neuroendocrine Tumors

Introduction: Platinum-based chemotherapy has been the recommended treatment for metastatic high-grade pancreatic neuroendocrine neoplasms (panNEN). This strategy has been questioned for pancreatic neuroendocrine tumor grade 3 (panNET G3). The most optimal treatment strategy for low/intermediate grade panNETs that show progression to a high grade (secondary panNET G3) is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mollazadegan K, Botling J, Welin S, Eriksson B, Skogseid B,

Keywords: pancreas, neuroendocrine tumor, treatment,

#1412 MiR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease

Introduction: This collaborative research plan aims at elucidating the glycolytic metabolism in advanced FDG-PET positive (+) and FDG-PET negative (-) small intestinal neuroendocrine tumor (SI-NET) patients treated with Lutetium peptide receptor radionuclide therapy (177Lu-PRRT).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Giandomenico V

Authors: Giandomenico V, Li S, Lind T, Boccherini M, Skogseid B,

Keywords: glycolytic metabolism, peptide receptor radionuclide therapy (PRRT), serum samples, miRNA, FDG-PET positive and-PET negative SI-NET patients,

#503 Long-Term Stable Disease with Everolimus in a Patient with Advanced Pancreatic Neuroendocrine Tumor Enrolled in RADIANT-1

Introduction: The phase II open-label RADIANT-1 study evaluated the safety and efficacy of Everolimus (E, 10 mg/d) ± octreotide LAR (O) in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) after chemotherapy failure. Objective tumor response was 9.6% in the E group and 4.4% in the E+O group (all partial), and stable disease (SD) was 68% and 80%.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Falkerby J, Granberg D, Eriksson B, Skogseid B, Öberg K,

Keywords: neuroendocrine, Everolimus, pancreatic,

#196 Efficacy and Safety of the Combination Streptozotocin, 5-FU in Endocrine Pancreatic Tumors: A Retrospective Study

Introduction: The combination of Streptozotocin with 5-FU has been used during the past decades in our institution as the first-line treatment in pancreatic NETs with low to moderate proliferation.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Antonodimitrakis P, Skogseid B, Hurtig M, Oberg K, Granberg D,

Keywords: Streptozotocin, 5-FU, endocrine pancreatic tumors, progression-free survival, side effects,